Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Harnessing Hematopoietic Stem Cell Breakthroughs to Pioneer Advances in Transplantation Therapies

Project description

Safer haematopoietic stem cell transplantation

Haematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of haematopoietic stem cells in order to re-establish blood cell production. Although it can be a life-saving treatment for severe blood and immune disorders, it is associated with toxicity and low engraftment rates. The ERC-funded eHSCT project aims to develop safer and more effective strategies to overcome these challenges. Researchers will use genome-wide screening to uncover key regulators of stem cell engraftment and movement in order to improve current mobilisation and transplantation approaches. Moreover, the project will explore alternative non-toxic conditioning strategies to improve the engraftment of infused cells. Collectively, project innovations are expected to make HSCT safer and less toxic.

Objective

Hematopoietic stem cell transplantation (HSCT) is a groundbreaking therapy that has transformed the treatment of severe hematological and immune disorders. It involves infusing healthy or corrected hematopoietic stem cells (HSCs) into a patient to restore their blood cell production. Despite its remarkable success, HSCT is currently limited to the most severe cases due to several key challenges. These bottlenecks include inefficient HSC mobilization, limited engraftment leading to insufficient clonal diversity, and the toxicity of chemotherapy-based conditioning regimens.
This comprehensive proposal outlines a transformative approach to address these limitations head-on, enhancing both the efficacy and safety of HSCT.

The project aims to:

1. Uncover the key factors governing HSC engraftment and egress: Using optimized genome-wide gain- and loss-of-function in vivo screening in HSCs, I will identify the pivotal players responsible for HSC engraftment and egress. These insights will inform the development of innovative mobilization strategies and the engineering of HSCs to confer a transient engraftment advantage.

2. Establish a mobilization-based conditioning regimen: I will exploit the temporary niche depletion induced by mobilizers to optimize a genotoxic-free regimen. By harnessing cell surface profiling data and potentially using mobilizer-resistant variants generated through directed evolution, I will tilt the competitive balance between freshly mobilized and infused HSCs, favoring the engraftment of infused cells.

This project seeks to pioneer avant-garde methods that enhance mobilization and engraftment while avoiding the use of toxic conditioning regimens, thereby addressing major HSCT limitations. These advancements hold the potential to transform HSCT into a safer, more broadly applicable therapy, extending its benefits to a wider demographic and diverse healthcare settings. This aligns with the ultimate objective of achieving global health equity.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

UNIVERSITA VITA-SALUTE SAN RAFFAELE
Net EU contribution
€ 1 500 000,00
Address
VIA OLGETTINA 58
20132 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 500 000,00

Beneficiaries (1)